文献速递药物相互作用

恩杂鲁胺降低前列腺癌男性羟考酮暴露

Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer.
PubMed 文献 · Clin Pharmacokinet · 2023-05-10

结果显示恩杂鲁胺使羟考酮AUC0-8h和Cmax分别降低44.7%和35.5%,活性代谢物奥昔吗酮暴露降低更显著,提示联合用药需关注镇痛疗效。

要点

  • 恩杂鲁胺使羟考酮AUC0-8h降低44.7%、Cmax降低35.5%。
  • 活性代谢物奥昔吗酮AUC0-8h降低74.2%、Cmax降低56.0%。
  • 恩杂鲁胺联合羟考酮时应考虑阿片暴露下降对镇痛效果的影响。

核心结论

  • 恩杂鲁胺与羟考酮联用显著降低前列腺癌男性患者羟考酮及其活性代谢物奥昔吗酮的暴露。
  • 处方恩杂鲁胺联合羟考酮时应将这一药物相互作用纳入考虑。

研究设计与样本

  • 前瞻性、非随机、开放标签、两臂平行研究。
  • 所有患者接受单剂15 mg速释羟考酮;恩杂鲁胺组接受恩杂鲁胺160 mg每日一次。
  • 采用经验证的液相色谱串联质谱法测定羟考酮及其代谢物血浆浓度。

主要发现

  • 恩杂鲁胺组较对照组羟考酮平均AUC0-8h降低44.7%(p < 0.001),Cmax降低35.5%(p = 0.004)。
  • 恩杂鲁胺组较对照组活性代谢物奥昔吗酮AUC0-8h降低74.2%(p < 0.001),Cmax降低56.0%(p = 0.001)。
  • 恩杂鲁胺显著增加无活性代谢物去甲羟考酮和去甲奥昔吗酮的AUC0-8h和Cmax。

临床怎么用

  • 对接受恩杂鲁胺治疗的前列腺癌患者处方羟考酮时,应意识到羟考酮及奥昔吗酮暴露可能显著下降。
  • 联合用药期间需关注镇痛效果,必要时评估疼痛控制并考虑调整阿片类药物方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Up to 90% of patients with castration-resistant prostate cancer (CRPC) will develop symptomatic bone metastases requiring pain medication, with opioids being the mainstay of therapy in treating moderate and severe pain. Enzalutamide is an androgen receptor antagonist for the treatment of CRPC and a strong inducer of cytochrome P450 (CYP)3A4. Hereby, enzalutamide potentially reduces the exposure of oxycodone, an opioid metabolized by CYP3A4 and CYP2D6. Our objective was to evaluate the potential drug-drug interaction of enzalutamide and oxycodone. METHODS: A prospective, nonrandomized, open-label, two-arm parallel study was performed. All patients received a single dose of 15 mg normal-release oxycodone. Patients in the enzalutamide arm (ENZ-arm) received enzalutamide 160 mg once daily. Plasma concentrations of oxycodone and its metabolites were quantified using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) method. RESULTS: Twenty-six patients (13 ENZ-arm; 13 control arm) were enrolled in the study. Enzalutamide decreased the mean AUC0-8 h and Cmax of oxycodone with, respectively, 44.7% (p < 0.001) and 35.5% (p = 0.004) compared with the control arm. The AUC0-8 h and Cmax of the active metabolite oxymorphone were 74.2% (p < 0.001) and 56.0% (p = 0.001) lower in the ENZ-arm compared with the control arm. In contrast, AUC0-8 h and Cmax of the inactive metabolites noroxycodone and noroxymorphone were significantly increased by enzalutamide. CONCLUSION: Co-administration of enzalutamide significantly reduced exposure to oxycodone and its active metabolite oxymorphone in men with prostate cancer. This should be taken into account when prescribing enzalutamide combined with oxycodone.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Detert Oude Weme SEH, Hulskotte LMG, Vervenne WL, et al. Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer. Clin Pharmacokinet. 2023. PMID: 37162620. doi:10.1007/s40262-023-01255-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。